★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets GLP-1 Obesity Drugs Likely to Have Significant Impact on Biopharma Share Prices and Non-Healthcare Sectors The development of a new GLP-1 receptor agonist at Viking Therapeutics helped the company's shares surge by 150% this week…McAlinden Research PartnersFebruary 28, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Billion Dollar Deals Abound as Big Pharma Continues Battle Against Patent Cliffs M&A activity among some of the largest pharmaceutical firms has gotten off to a hot start in 2024, with several…McAlinden Research PartnersJanuary 10, 2024
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Big Pharma Consolidates Its Hold on Financing for Desperate Biotech Sector, M&A to Gain Steam in 2024 Big pharma M&A activity in the new year is expected to expand, continuing a trend that gained steam throughout 2023.…McAlinden Research PartnersDecember 19, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Pfizer and Moderna Look to Put COVID Bust Behind Them, Add New Drug Development to Pipelines Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…McAlinden Research PartnersOctober 18, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets FTC Settles Suit Over Amgen-Horizon Deal, Potentially Averting Further Pharma M&A Hurdles The FTC's settlement with Amgen and Horizon has cleared the way for the two companies to complete a $27.8 billion…McAlinden Research PartnersSeptember 5, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareEconomics & Trade China Looks to Recharge Foreign Investment with Focus on Burgeoning Biopharma Business Some gauges indicate that foreign investment in China has sunken to 25-year lows recently. Beijing sees development of the country's biotechnology…McAlinden Research PartnersAugust 15, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsManufacturing & LogisticsMarkets Obesity Drugs’ Popularity Promises to Inject New Life Into Pharma Pipelines Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…McAlinden Research PartnersJuly 25, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarketsPolitics & Policy Psychedelics Break New Ground in Clinical Trials, Research to be Bolstered by Key FDA Guidance New FDA guidance meant to steer clinical trials of psychedelic compounds will play a major role in the eventual approval…McAlinden Research PartnersJuly 12, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…McAlinden Research PartnersMay 25, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Johnson & Johnson Faces Patent Hurdles in Drug Business, Potentially Setting the Tone for Pharma Peers Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…McAlinden Research PartnersApril 18, 2023